massive transfusion copy
TRANSCRIPT
-
8/11/2019 Massive Transfusion Copy
1/17
Massive Transfusion
-
8/11/2019 Massive Transfusion Copy
2/17
Definition
>= 10 RBC units within 24 h
> 4 RBC units in 1 hr with anticipation
of continued need for transfusion
Replacement of > 50% of TBV within 3
hr
-
8/11/2019 Massive Transfusion Copy
3/17
Epidemiology of MT
Variety of clinical settings
Trauma, obstetric, major surgery
Uncontrolled bleeding
40% trauma related mortality
#1 cause of maternal mortality worldwide
-
8/11/2019 Massive Transfusion Copy
4/17
Pathophysiology changes
-
8/11/2019 Massive Transfusion Copy
5/17
3 components
ETIC (early trauma-induced coagulopathy) Tissue injurytissue factorcoagulationDIC
Hyperfibrinolysis Hypoperfusionthrombomodulin expression EC
enhance plasmin formationfibrinolysis
Prominent in obstetric haemorrhage
Infusion of crystalloid, bloods -> dilutionalcoagulopathy, acidosis, hypocalcemia &hypothermia
-
8/11/2019 Massive Transfusion Copy
6/17
Clinical Mx of MT
Massive transfusion protocol
Early recognition of pt requiring MT, facilitate
communications between different services
and avoid delay in clinical care
Demonstrated to improve patients survival,
reduced rates of organ failure.
-
8/11/2019 Massive Transfusion Copy
7/17
Blood products
Optimal transfusion ratio
Blood: plasma :platelets = 1: 1: 1 (645ml)
Resembles whole blood
Haematocrit 26%, coag activity 50% & plt
count of 90 000microL
Evidence supported by US military & then
civilian studies
Pragmatic Randomized Optimal Platelet&
Plasma Ratios (PROPPR)
-
8/11/2019 Massive Transfusion Copy
8/17
Trigger level for blood
components transfusion
Insufficient data to identify an INR,
fibrinogen level or platelet count to
trigger a blood component transfusion
NBA guidelines
Suggested doses
FFP 15ml/kg Platelets: 1 adult therapeutic dose
Cryoprecipitate 3-4 g
-
8/11/2019 Massive Transfusion Copy
9/17
Values indicative of critical
physiologic derangement
Temperature < 35
pH < 7.2, BE >-6, lactate >4
Ionised calcium < 1.1mmol/L
Plt count < 50x109/L
PT > 1.5 x normal
INR > 1.5
APTT > 1.5xnormal
Fibrinogen level < 1.0
-
8/11/2019 Massive Transfusion Copy
10/17
Pharmacological therapy
rFVIIa No effect on 48hr or 30 day mortality
Blunt trauma reduced RBC transfusion req& ARDS
Penetrating trauma no effect on morbidity
90mcg/kg
Prothombinex Indicated for warfarin reversal
Insufficient evidence to support the generaluse in MT
-
8/11/2019 Massive Transfusion Copy
11/17
Pharmacological therapy
TXA
CRASH 2 trial international multicentre RCT Improved survival in trauma patients
Obstetric setting Suggested reduces blood loss @ CS & the risk of progression
to severe PPH
RCT is currently investigating the effect of TXA in treatingPPH
-
8/11/2019 Massive Transfusion Copy
12/17
Laboratory monitoring
Assessment of status O2 carrying capacity, haemostasis, metabolic
Conventional testing has limited utility Coagulation panel
Not available in real time fashion
Do not detect all haemostatic abnormalities such ashyperfibrinolysis
Use of Point-of-care testing is increasing
-
8/11/2019 Massive Transfusion Copy
13/17
Laboratory monitoring
Thromboelastograph (TEG)
Point- of- care Haemostasis assay
Shorter turn-around time (15 mins)
Detect hyperfibrinolysis
Detect coagulopathy due to hypothermia
Shown to reduce transfusion requirement /MTin major surgery
-
8/11/2019 Massive Transfusion Copy
14/17
R = reaction time (s); time of latency from start of test to initial fibrin formation
K = kinetics (s); time taken to achieve a certain level of clot strength (amplitude of
20mm)
alpha = angle (slope between R and K); measures the speed at which fibrin build
up and cross linking takes place, hence assesses the rate of clot formationTMA = time to maximum amplitude(s)
MA = maximum amplitude (mm); represents the ultimate strength of the fibrin clot
A30 or LY30 = amplitude at 30 minutes; percentage decrease in amplitude at 30
minutes post-MA and gives measure of degree of fibrinolysis
CLT = clot lysis time (s)
-
8/11/2019 Massive Transfusion Copy
15/17
TEG AS A GUIDE TO TREATMENT
Increased R time => FFP
Decreased angle => cryopreciptate
Decreased MA => platelets (consider
DDAVP)
Fibrinolysis => transexamic acid (oraprotinin)
-
8/11/2019 Massive Transfusion Copy
16/17
Conclusions
MT protocol is important
Early transfusion of blood products in ratio of 1:1:1may reduce mortality & improve patient outcome butfurther RCT needed to determine optimal ratio
TXA improved survival in several RCT and should beused in MT
New laboratory monitoring, such as TEG mightimprove patient outcome when used in combinationwith MTP
-
8/11/2019 Massive Transfusion Copy
17/17
Reference
Update on Massive Transfusion. H.P Pham, B.H Shaz. Br. J. Anaesth. (2013)
111 (suppl 1): i71-i82.
Patient Blood Management Guidelines: Module 1. Critical Bleeding Massive
Transfusion. National Blood Authority, 2011.
Life in the
Fastlanehttp://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/.
http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/http://lifeinthefastlane.com/education/ccc/thromboelastogram-teg/